Literature DB >> 32400927

COVID-19 and childhood acute lymphoblastic leukemia.

Jeffrey W Taub1, Yubin Ge2, Ana C Xavier3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32400927      PMCID: PMC7235492          DOI: 10.1002/pbc.28400

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.838


× No keyword cloud information.
To the Editor: Young children are not affected with life‐threatening illnesses from the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) compared to the adult population, despite having no immunity to this novel infectious agent. The coronavirus disease 2019 (COVID‐19) pandemic may, however, impact the pediatric population in a different manner that may become more evident once it ends. Acute lymphoblastic leukemia (ALL), the most common form of childhood cancer, has an overall incidence in the United States of 34 cases/ million individuals <20 years of age with the peak incidence of 75.2 cases/ million occurring in children between the ages of 1‐4 years. Hypotheses have been proposed, particularly by Dr Greaves, that account for the peak incidence in early childhood. In Greaves’ model, ALL arises by “two‐hits”; the “first‐hit” occurring prenatally with the generation of a preleukemia clone which may harbor a leukemia‐associated genetic change (eg, ETV6‐RUNX1 fusion translocation). A subsequent “second‐hit” occurring postnatally in a population of “preleukemia” cells would initiate the final steps for leukemia to develop and manifest clinically. Interesting, the ETV6‐RUNX1 fusion has been detected in up to 5% of healthy newborn blood samples, as an example of a relatively high proportion of children potentially harboring a “first‐hit” preleukemia clone. Without a “second‐hit,” these children would not develop ALL. The “second‐hit” is postulated to be exposure to a common infectious agent (eg, virus) in a susceptible child whose body harbors a population of preleukemia cells, although they have no immunity against the infection. This “perfect storm” may lead to an abnormal or overstimulated immune response leading to the proliferation of leukemia cells. Measures have been implemented to control the spread of COVID‐19, including social distancing with widespread closure of schools, businesses, and entertainment venues. Within a span of 2 months (March to April 2020), our respective children's hospitals (situated hundreds of miles apart in different states) have observed a marked reduction in the number of both emergency room visits and number of hospitalized children during the typical winter season when the various seasonal respiratory viruses including influenza and RSV circulate among the population. Can the isolation of children at home lead to an avoidance of exposure to viruses and the leukemia‐inducing “second‐hit?” Will this result in a decreased number of childhood ALL cases in the near future? Conversely, can the infection of predisposed children by COVID‐19 (even those who may be clinically asymptomatic) act as a “second‐hit,” leading to an increased number of ALL cases following this pandemic? Interestingly, in 2003, a decreased number of pediatric ALL cases were diagnosed in Hong Kong following the severe acute respiratory syndrome (SARS) outbreak. The answers to these two potential scenarios may become evident in the near future with ongoing epidemiologic surveillance.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.
  5 in total

1.  Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening.

Authors:  Daniel Schäfer; Marianne Olsen; David Lähnemann; Martin Stanulla; Robert Slany; Kjeld Schmiegelow; Arndt Borkhardt; Ute Fischer
Journal:  Blood       Date:  2018-01-08       Impact factor: 22.113

Review 2.  A causal mechanism for childhood acute lymphoblastic leukaemia.

Authors:  Mel Greaves
Journal:  Nat Rev Cancer       Date:  2018-08       Impact factor: 60.716

3.  High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia.

Authors:  Jeffrey W Taub; Mark A Konrad; Yubin Ge; John M Naber; Jackie S Scott; Larry H Matherly; Yaddanapudi Ravindranath
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

4.  Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - United States, 2001-2014.

Authors:  David A Siegel; S Jane Henley; Jun Li; Lori A Pollack; Elizabeth A Van Dyne; Arica White
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-09-15       Impact factor: 17.586

Review 5.  Impact of SARS on development of childhood acute lymphoblastic leukaemia.

Authors:  C K Li; B Zee; J Lee; K W Chik; S Y Ha; V Lee
Journal:  Leukemia       Date:  2007-07       Impact factor: 11.528

  5 in total
  2 in total

1.  Acute Leukemia in children after recent COVID-19 infection. Possible association?

Authors:  M Ioannidou; A Tragiannidis; E Hatzipantelis
Journal:  Hippokratia       Date:  2021 Jan-Mar       Impact factor: 0.471

Review 2.  Etiology of Acute Leukemia: A Review.

Authors:  Cameron K Tebbi
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.